RxDoctor Payments Data

Richard Winkler, MD

Family Medicine · Turlock, CANPI 1780763631

Payments from drug & device makers

$834in general payments, 2019–2025

Across 104 payments — averaging $8.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$723
  • GSK$65
  • AbbVie$22
  • Sanofi-aventis U.S. LLC$13
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$82399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk98$723
GSK3$65
AbbVie1$22
Sanofi-aventis U.S. LLC1$13
Lilly USA, LLC1$12

How this compares

$834 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$2,843
Medicare patients
28
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide117$191,485
JardianceEmpagliflozin92$115,661
OzempicSemaglutide73$88,184
EliquisApixaban98$83,048
XareltoRivaroxaban66$69,122
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$64,243
JanuviaSitagliptin Phosphate35$54,675
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$38,947
TrulicityDulaglutide20$31,236
Tresiba Flextouch U-200Insulin Degludec20$24,770
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$21,417
Soliqua 100-33Insulin Glargine/Lixisenatide13$18,019
LantusInsulin Glargine,hum.Rec.Anlog74$15,497
MyrbetriqMirabegron13$15,334
Lantus SolostarInsulin Glargine,hum.Rec.Anlog117$15,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$723$279,669190 claims
GSKTrelegy Ellipta, Breo Ellipta$65$50,46966 claims
Lilly USA, LLCTrulicity, Humulin N$12$35,55639 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$13$33,51687 claims
AbbVieSynthroid$22$3,65634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →